Healthcare Private Placement and M&A Transactions Review

Strategy | Financing | Macro & Markets

Share Silverwood Weekly Healthcare Market Update

Private Placement / Financing Transactions

Crystalys Therapeutics: The company raised $130 million of Series B venture funding in a deal led by Frazier Healthcare Partners on July 22, 2026, putting the company’s pre-money valuation at $459 million. The company is an operator of a biopharmaceutical business intended to address the significant unmet medical needs of people living with gout.Hilo Health: The company raised $61 million of Series B venture funding in a deal led by Earlybird Venture Capital and Wellington Partners on July 22, 2026. The company is a developer of cuffless blood pressure monitoring technology for continuous cardiovascular tracking.TYBR Health: The company raised $30 million of Series A venture funding in a deal led by Vensana Capital and Mutual Capital Partners on July 21, 2026, putting the company’s pre-money valuation at $36 million. The company is a developer of a collagen-based resorbable hydrogel designed to protect healing tendons and ligaments and support recovery after surgery.Transcripta Bio: The company raised $24 million of venture funding from Mayo Clinic, Omnimed Capital and BlueYard Capital on July 22, 2026. The company is a developer of an artificial intelligence-driven drug discovery platform designed for accelerating therapeutic development.Elio: The company raised $21 million of Series A venture funding in a deal led by Xora Innovation and Innovation Endeavors Management Company on July 23, 2026. The company is a developer of optical computing technology that embeds computation into sensing systems for biological sample analysis.TidalSense: The company raised $19 million of venture funding from BGF, Airstream Capital and Foresight Group on July 24, 2026. The company is a developer of AI-driven respiratory diagnostic and monitoring technologies designed to build novel sensor tools that can detect changes in lung function.Magnendo: The company raised $18 million of Series A venture funding in a deal led by Penumbra on July 24, 2026. The company is a developer of an AI-powered medical imaging platform designed to assist clinicians in detecting and analyzing gastrointestinal conditions with improved accuracy.Karoo Health: The company raised $16.2 million of Series A venture funding in a deal led by 7wire Ventures and Allumia Ventures Management on July 21, 2026, putting the company’s pre-money valuation at $33.8 million. The company is an operator of a care management business intended to help healthcare organizations transition from the traditional fee-for-service to a value-based care model.Blue Arbor Technologies: The company raised Series A venture funding in a deal led by Ottobock on July 20, 2026, putting the company’s pre-money valuation at $28.4 million. The company is a developer of implantable neuromuscular interface systems designed to improve control of advanced prosthetic devices.Dimer Instruments: The company raised Series A venture funding from undisclosed investors on July 23, 2026, putting the company’s pre-money valuation at $19.5 million. The company is a manufacturer of real-time analytical instruments designed for monitoring and optimizing pharmaceutical manufacturing processes.Holobiome: The company raised $10 million of venture funding in the form of SAFE Notes from undisclosed investors on July 22, 2026. The company is a developer of microbiome-derived therapies and targeted probiotic solutions for human health.Magvation: The company raised venture funding from undisclosed investors on July 22, 2026. The company is a developer of an AI-powered collaborative robot designed to reduce preventable error-causing factors in the operating room.Brava: The company raised venture funding from undisclosed investors on July 23, 2026. The company is a developer of lingual orthodontic braces that use independent tooth-moving technology.N-Zyme Biomedical: The company raised $4.6 million of Series A venture funding from undisclosed investors on July 21, 2026. The company is a developer of biopharmaceutical therapeutics designed to treat laryngopharyngeal reflux.Medyria: The company raised CHF 3.5 million of venture funding from undisclosed investors on July 24, 2026. The company is a developer of a physiology assessment device intended to advance the diagnosis and treatment of heart ischemia.Ascendia Pharmaceuticals: The company received development capital from undisclosed investors on July 24, 2026. The company is an operator of a contract-development-and-manufacturing business dedicated to the development of enhanced formulations for pre-clinical and clinical-stage drug candidates and marketed drug products.Uviquity: The company raised $4 million of venture funding in the form of convertible debt from undisclosed investors on July 21, 2026. The company is a developer of semiconductor chips designed to generate human-safe, pathogen-eliminating far-ultraviolet C light.Affinity Biosensors: The company raised venture funding from undisclosed investors on July 23, 2026. The company is a developer of an antimicrobial susceptibility testing device designed for rapid measurement and observation of bacterial growth and response.Reselute: The company raised Series A venture funding from Charlotte Angel Fund, Band of Angels and other undisclosed investors on July 22, 2026, putting the company’s pre-money valuation at $10.6 million. The company is an operator of a medical technology business intended for treating orthopedic implant-related infections.HALO X-ray Technologies: The company raised an undisclosed amount of venture funding from Agilent Technologies, Midlands Engine Investment Fund, and UK Innovation & Science Seed Fund on July 20, 2026. The company is a developer of X-ray diffraction screening technology designed to improve material identification and security screening.

M&A Transactions

ArisGlobal / Dassault Systemes: The company reached a definitive agreement to be acquired by Dassault Systemes, a subsidiary of Dassault Group, for an estimated $2 billion on July 23, 2026. The company is a developer of AI-powered life sciences software platforms intended for drug development, safety monitoring, regulatory compliance, quality management, and medical affairs operations.Biolife Solutions / Repligen: The company reached a definitive agreement to be acquired by Repligen for $1.5 billion on July 22, 2026. The company is a provider of biopreservation media, cell processing systems and supply chain tools for cell and gene therapy manufacturing.Personalis / Tempus AI: The company reached a definitive agreement to be acquired by Tempus AI for $1.5 billion on July 20, 2026. The company is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies.AdaptHealth Diabetes Health Business / Cardinal Health: The company, a subsidiary of AdaptHealth was acquired by Cardinal Health for $235 million on July 20, 2026. The company is an operator of a diabetes treatment business.Atonarp / VAT Group: The company reached a definitive agreement to be acquired by VAT Group for an estimated CHF 110 million on July 22, 2026. The company is a manufacturer of a cloud-connected mass spectrometer intended to quantitatively analyze chemical processes in real-time.Strive Medical / Cardinal Health: The company reached a definitive agreement to be acquired by Cardinal Health for an estimated $125 million on July 20, 2026. The company is a distributor of urology, wound care, and incontinence medical supplies catering to physicians, urologists, wound care experts, and healthcare facilities.Freenome / Perceptive Capital Solutions: The company acquired Perceptive Capital Solutions for an estimated $70 million through a reverse merger, resulting in the combined entity trading on the NASDAQ Stock Exchange under the ticker symbol FRNM on July 20, 2026. The company is a developer of blood-based multi-omics tests for early cancer detection.A1 Biochem Group / Apitoria Pharma Private: The company reached a definitive agreement to be acquired by Apitoria Pharma Private, a subsidiary of Aurobindo Pharma, for $13.6 million on July 23, 2026. The company is a provider of contract research services intended for the pharmaceutical and biotechnology sectors.Aptorum Group / DiamiR Biosciences (Niki BioSolutions): The company completed an all-stock merger with DiamiR Biosciences on July 20, 2026, creating the newly renamed Niki BioSolutions, Inc. trading on the NASDAQ Stock Exchange under the ticker symbol NIKI on July 20, 2026. The company is a molecular diagnostics developer focused on microRNA-based blood tests for neurodegenerative and other diseases.Memo Therapeutics / Ipsen: The company was acquired by Ipsen for EUR 200 million with total potential consideration reaching EUR 700 million on July 22, 2026. The company is a developer of an antibody discovery and immune repertoire analysis platform designed to transform the lives of patients with virus infections and cancer.NanoCellect Biomedical / Nova Biomedical: The company was acquired by Nova Biomedical, via its financial sponsor Patricia Industries, through an LBO on July 24, 2026 for an undisclosed amount. The company is a manufacturer of microfluidic cell sorters designed for maintaining cell viability and integrity.Neuphoria Therapeutics / Scancell Holdings: The company reached a definitive agreement to be acquired by Scancell Holdings for an undisclosed amount on July 23, 2026. The company is a clinical-stage biotechnology developer of therapies for neuropsychiatric and neurological disorders.ThermaZone / Gentherm: The company was acquired by Gentherm for an undisclosed amount on July 22, 2026. The company is a manufacturer of portable thermoelectric hot and cold therapy devices for pain management.

Source: Pitchbook Data, Inc.
Connect on LinkedIn with Jonathan Hodson-Walker